DHODH - dihydroorotate dehydrogenase (quinone) Gene

中文名称：二氢乳清酸脱氢酶 (醌)

种属: Homo sapiens

同用名: URA1; POADS; DHOdehase

基因 ID: 1723 | 基因类型: protein coding

关于 DHODH

Cytogenetic location: 16q22.2 Genomic coordinates (GRCh38): 16:72,008,744-72,027,659 (from NCBI)

This gene has 9 transcripts (splice variants), 173 orthologues, 2 paralogues and is associated with 3 phenotypes. Ubiquitous expression in liver (RPKM 7.8), kidney (RPKM 1.7) and 24 other tissues.

功能概要

由该基因编码的蛋白质在嘧啶从头生物合成中催化第四个酶促步骤，即泛醌介导的二氢乳清酸氧化为乳清酸。这种蛋白质是一种位于线粒体内膜外表面的线粒体蛋白质。[RefSeq 提供，2008 年 7 月]

The protein encoded by this gene catalyzes the fourth enzymatic step, the ubiquinone-mediated oxidation of dihydroorotate to orotate, in de novo pyrimidine biosynthesis. This protein is a mitochondrial protein located on the outer surface of the inner mitochondrial membrane. [provided by RefSeq, Jul 2008]

DHODH 基因产物(4)

mRNA	Protein	Name
NM_001361.5	NP_001352.2	dihydroorotate dehydrogenase (quinone), mitochondrial
NM_001025193.1
XM_005255829.5	XP_005255886.1	dihydroorotate dehydrogenase (quinone), mitochondrial isoform X2
XM_047433674.1	XP_047289630.1	dihydroorotate dehydrogenase (quinone), mitochondrial isoform X1

基因本体论

分子功能

分子功能 GO 注释	逻辑证据	参考文献	来源
enables dihydroorotate dehydrogenase (quinone) activity	IDA IDA: 通过直接分析推断	8925840	GOA
enables protein binding	IPI IPI: 通过物理相互作用推断	32296183	GOA

EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

DHODH 蛋白结构

DHO_dh

0
100
200
300
395 a.a.

蛋白主名

其他名称

dihydroorotate dehydrogenase (quinone), mitochondrial

dihydroorotate oxidase

human complement of yeast URA1

DHODH 蛋白互作信息

分类	蛋白名称	蛋白编号	互作蛋白	互作蛋白种属	互作蛋白编号	实验方法	参考文献
种属内	DHODH	Q02127	RNF19B	Homo sapiens	Q6ZMZ0	Validated Y2H	32296183
种属内	DHODH	Q02127	RNF19B	Homo sapiens	Q6ZMZ0	Y2H Array	32296183
种属内	DHODH	Q02127	RNF19B	Homo sapiens	Q6ZMZ0	Y2H Prey Pooling	32296183

种属间: 跨种属相互作用 种属内: 同种属相互作用

关联疾病

疾病名称

别名

Orotic Aciduria

Hereditary Orotic Aciduria	Orotidylic Pyrophosphorylase And Orotidylic Decarboxylase Deficiency
Uridine Monophosphate Synthase Deficiency	Umps Deficiency
Uridine Monophosphate Synthetase Deficiency	Orotic Aciduria I
Orotate Phosphoribosyltransferase And Orotidylic Decarboxylase Deficiency	Oprt And Odc Deficiency
Ump Synthase Deficiency	Orotic Aciduria Ii
Oroticaciduria 1	Orotic Aciduria Hereditary
Orotic Aciduria Type 1	Hereditary Orotic Aciduria Without Megaloblastic Anemia
Orotate Phosphoribosyltransferase And Omp Decarboxylase Deficiency	Ump Synthtase Deficiency
Umps	Orotidylic Decarboxylase Deficiency
Orotic Aciduria 1	ORAC1
Aciduria, Orotic	Hereditary Orotic Aciduria, Type 1
Orotic Aciduria Nos	Orotaciduric Anaemia
Orotic Aciduria Anaemia	Orotic Aciduria Megaloblastic Anaemia

Progressive Relapsing Multiple Sclerosis

Prms	Progressive-Relapsing Ms
Multiple Sclerosis, Progressive Relapsing

Progressive Multifocal Leukoencephalopathy

Pml	Leukoencephalopathy, Progressive Multifocal
Progressive Multifocal Leukoencephalitis	Leukoencephalopathy Progressive Multifocal
Pml - [Progressive Multifocal Leukoencephalopathy]

Acrofacial Dysostosis 1, Nager Type

Nager Syndrome	Nager Acrofacial Dysostosis
AFD1	Preaxial Acrofacial Dysostosis
Mandibulofacial Dysostosis, Treacher Collins Type, With Limb Anomalies	Afd, Nager Type
Nager Acrofacial Dysostosis Syndrome	Nafd
Acrofacial Dysostosis, Nager Type	Afd
Preaxial Manibulofacial Dysostosis	Split Hand Deformity-Mandibulofacial Dysostosis
Preaxial Mandibulofacial Dysostosis	Mandibulofacial Dysostosis With Preaxial Limb Anomalies
Preaxial Acrodysostosis	Afd Nager Type
Mandibulofacial Dysostosis Treacher Collins Type With Limb Anomalies

Parasitic Protozoa Infectious Disease

Protozoan Infections	Mastigophora Infectious Disease
Sarcomastigophora Infectious Disease

Fusariosis

Fusarium Infection

Dysostosis

Dysostoses

Postaxial Acrofacial Dysostosis

Miller Syndrome	POADS
Genee-Wiedemann Syndrome	Postaxial Acrodysostosis
Genee-Wiedemann Acrofacial Dysostosis	Acrofacial Dysostosis, Genee-Wiedmann Type
Mandibulfacial Dysostosis With Postaxial Limb Anomalies	Gwafd
Poads Syndrome	Postaxial Acrofacial Dysostosis Syndrome
Wildervanck-Smith Syndrome	Acrofacial Dysostosis, Genee-Wiedemann Type
Mandibulofacial Dysostosis With Postaxial Limb Anomalies	Genée-Wiedemann Syndrome
Chromosome 11p Deletion Syndrome

Acrofacial Dysostosis

Malaria

Malaria, Susceptibility To	Malaria, Resistance To
Malaria, Cerebral	Cerebral Malaria
Malaria, Severe, Susceptibility To	Malaria, Severe, Resistance To
Malaria, Cerebral, Susceptibility To	Induced Malaria
Malaria, Vivax, Protection Against	Malaria, Severe
Malaria, Cerebral, Reduced Risk Of	Malaria, Protection Against
Resistance To Malaria Due To G6pd Deficiency	Malaria Due To G6pd Deficiency
Malarial Encephalitis	CM
Malaria Cerebral	Susceptibility To Malaria
Acute Pernicious Fever	Aestivo-Autumnal Fever
Aestivo Autumnal Malaria	Chagres Fever
Continued Malaria Fever	Estivo-Autumnal Fever
Estivo-Autumnal Malaria	Estivo-Autumnal Malarial Fever
Falciparum Fever	Malignant Tertian Fever
Malignant Tertian Malaria	Pernicious Intermittent Fever
Pernicious Malaria	Quotidian Malaria
Subtertian Fever	Subtertian Malaria Fever
Subtertian Malignant Tertian Malaria	Tropical Malaria
Algid Malaria	Bilious Haemoglobinuric Fever
Black Water Fever	Blackwater Fever
Malarial Blackwater Fever	Severe Malarial Falciparum
West African Fever	Malarial Haematinuria
Haemoglobinuric Fever	Haemoglobinuric Malaria
Severe Plasmodium Falciparum Malaria	Malarial Haemoglobinuria
Malarial Haematuria	Falciparum Malaria [Malignant Tertian]
Malaria Tropica	Malarial Shock
Chagres Virus Disease	Malignant Malaria
Mtm - [Malignant Tertian Malaria]	Tm -[Malignant Tertian Malaria]
Panama Fever	St - [Subtertian Malaria]
Malarial Quotidian	Benign Tertian Malaria
Tertian Ague	Vivax Fever
Plasmodium Vivax Malaria Nos	Btm - [Benign Tertian Malaria]
Bt - [Benign Tertian Malaria]	Vivax Malaria
Benign Tertian Vivax Malaria	Tertian Malaria
Quartan Malaria	Quartan Ague
Quartan Fever	Plasmodium Malariae Malaria Nos
Quartan Malarial	Malaria By Plasmodium Malariae
Malariae Malaria	Ovale Tertian Malaria
Plasmodium Ovale Fever	Malaria Fever By Plasmodium Ovale
Ovale Malaria	Malaria By Plasmodium Ovale
Malarial Ovale	Marsh Fever
Remittent Congestive Fever	Coastal Fever
Remittent Gastric Fever	Miasmatic Fever
Congestive Remittent Fever	Intermittent Fever
Jungle Fever	Paludism
Cameroon Fever	Ague
Corsican Fever	Intermittent Bilious Fever
Disease Due To Plasmodiidae	Malarial Fever
Plasmodiosis	Remittent Fever
Roman Fever	Malaria Fever Nos
Malaria Nos	Paludal Fever
Clinically Diagnosed Malaria	Clinically Diagnosed Malaria Without Parasitological Confirmation
Congestive Fever	Malarial Cachexia
Marsh Cachexia	Paludal Cachexia
Recurrent Malaria	Remittent Malaria

Autoimmune Disease

Autoimmune Diseases	Autoimmune Hypersensitivity Disease
Hypersensitivity Reaction Type Ii Disease	Type Ii Hypersensitivity Reaction Disease

Pyrimidine Metabolic Disorder

Disorder Of Pyrimidine Metabolism

Pyrimidine Metabolism Disorder

Rheumatoid Arthritis

RA	Arthritis, Rheumatoid
Rheumatoid Arthritis, Susceptibility To	Arthritis Or Polyarthritis, Rheumatic
Atrophic Arthritis	Rheumatism Arthritis
Rheumatoid Polyarthritis

Primary Progressive Multiple Sclerosis

Ppms	Primary-Progressive Ms
Multiple Sclerosis, Primary Progressive

疾病名称	别名
Waldenstroem'S Macroglobulinemia	Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma

相关产品

Approval

生物活性分子 (5)

目录号	产品名	作用方式	纯度	是否罕见病
HY-B0083	Leflunomide	Inhibitor	99.82%	是
HY-N0157	Orotic acid	Chemical	99.98%	否
HY-110159	(E/Z)-Teriflunomide	Inhibitor	99.87%	是
HY-N0157A	Orotic acid zinc	Chemical	99.84%	否
HY-N0157R	Orotic acid (Standard)	Chemical	99.51%	否

Clinical Phase

生物活性分子 (7)

目录号	产品名	作用方式	纯度	Phase
HY-104029	Olorofim	Inhibitor	99.57%	Phase 3
HY-108325	Brequinar	Inhibitor	99.89%	Phase 2
HY-14908	Vidofludimus		99.14%	Phase 2
HY-129239	Farudodstat		99.68%	Phase 2
HY-175352	Nurr1 Agonist 14		/	Phase 2
HY-112645	BAY-2402234	Inhibitor	99.88%	Phase 1
HY-137463	AG-636	Inhibitor	98.25%	Phase 1

Pre-clinical Phase

生物活性分子 (63)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-W015495	L-Dihydroorotic acid	Substrate	99.94%	否
HY-124593	PTC299	Inhibitor	99.89%	否
HY-N6961	Lapachol	Inhibitor	98.67%	否
HY-15510	Tenovin-6		98.00%	否
HY-139189	DHODH-IN-16	Inhibitor	99.88%	否
HY-13423	Tenovin-1		99.88%	否
HY-100688	ML390	Inhibitor	99.72%	否
HY-128068	DHODH-IN-17	Inhibitor	99.91%	否
HY-15510B	Tenovin-6 Hydrochloride		98.88%	否
HY-135282	DHODH-IN-1	Inhibitor	98.65%	否
HY-N0157S1	Orotic acid-13C,15N2 monohydrate		99.93%	否
HY-101813	Laflunimus	Inhibitor	99.70%	否
HY-153112	DHODH-IN-23	Inhibitor	99.82%	否
HY-132170	DSM502	Inhibitor	99.74%	否
HY-132171A	DSM705 hydrochloride	Inhibitor	99.56%	否
HY-132174	CHIKV-IN-2	Inhibitor	99.21%	否
HY-128787	hDHODH-IN-4	Inhibitor	99.73%	否
HY-135664	hDHODH-IN-5	Inhibitor	98.55%	否
HY-135675	DHODH-IN-11	Inhibitor	99.69%	否
HY-135678	DHODH-IN-14	Inhibitor	99.81%	否
HY-N3097	Pellitorine		99.84%	否
HY-N7961	(E/Z)-Ginkgolic acid C17:2	Inhibitor	99.37%	否
HY-RS03734	DHODH Human Pre-designed siRNA Set A	Pre-designed Set	/	否
HY-132171	DSM705	Inhibitor	/	否
HY-14908A	Vidofludimus hemicalcium		/	否
HY-135562	Ascofuranone	Inhibitor	/	否
HY-135618	DHODH-IN-3	Inhibitor	/	否
HY-135619	DHODH-IN-4	Inhibitor	/	否
HY-135666	DHODH-IN-8	Inhibitor	/	否
HY-135667	hDHODH-IN-7	Inhibitor	/	否
HY-135676	DHODH-IN-12	Inhibitor	/	否
HY-135677	DHODH-IN-13	Inhibitor	/	否
HY-135679	DHODH-IN-15	Inhibitor	/	否
HY-139825	Indoluidin E	Inhibitor	/	否
HY-139889	DHODH-IN-18	Inhibitor	/	否
HY-142834	RORγt/DHODH-IN-2	Inhibitor	/	否
HY-142843	RORγt/DHODH-IN-1	Inhibitor	/	否
HY-142847	RORγt/DHODH-IN-3	Inhibitor	/	否
HY-144169	DHODH-IN-19	Inhibitor	/	否
HY-144371	DHODH-IN-20	Inhibitor	/	否
HY-146317	P1788	Inhibitor	/	否
HY-148395	UCK2 Inhibitor-2	Inhibitor	/	否
HY-148396	UCK2 Inhibitor-3		/	否
HY-149030	DHODH-IN-21	Inhibitor	/	否
HY-149031	DHODH-IN-22	Inhibitor	/	否
HY-149877	hDHODH-IN-12	Inhibitor	/	否
HY-158023	DHODH-IN-26		/	否
HY-163158	DHODH-IN-24	Inhibitor	/	否
HY-163328	DHODH-IN-25	Inhibitor	/	否
HY-174816	DHODH-IN-28	Inhibitor	/	否
HY-175259	DHODH-IN-29	Inhibitor	/	否
HY-176728	DHODH-IN-27	Inhibitor	/	否
HY-B0083S	Leflunomide-d4	Inhibitor	/	否
HY-RS03735	Dhodh Mouse Pre-designed siRNA Set A	Pre-designed Set	/	否
HY-RS03736	Dhodh Rat Pre-designed siRNA Set A	Pre-designed Set	/	否
HY-108325S	Brequinar-d3	Inhibitor	/	否
HY-120462	Genz-669178	Inhibitor	/	否
HY-129253	GSK984	Control	/	否
HY-169220S	RORγ/DHODH-IN-1	Inhibitor	/	否
HY-169222S	RORγ/DHODH-IN-2	Inhibitor	/	否
HY-175423	DHODH-IN-30	Inhibitor	/	否
HY-B0083S1	Leflunomide-13C6	Inhibitor	/	否
HY-120924	BRD9185	Inhibitor	/	否

直系同源

种属	基因名	来源	基因 ID
Mus musculus	DHODH	MGD	MGI:1928378
Canis familiaris	DHODH	VGNC	VGNC:53333
Rattus norvegicus	DHODH	RGD	RGD:68352

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4